CUSP06 is a CDH6-directed ADC with a differentiated profile and potentially best-in-class activity CUSP06 demonstrated a manageable safety profile, consistent with other TOP1-inhibitor ADCs Promising signs of efficacy were observed in patients with heavily pretreated platinum-resistant...
Hence then, the article about oncusp therapeutics announces encouraging initial phase 1a results from ongoing first in human study evaluating its cdh6 directed antibody drug conjugate cusp06 in platinum refractory resistant ovarian cancer and other advanced solid tumo was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( OnCusp Therapeutics Announces Encouraging Initial Phase 1a Results from Ongoing First-in-Human Study Evaluating its CDH6-Directed Antibody-Drug Conjugate, CUSP06, in Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumo )
Also on site :
- Sandra Bullock Seemingly Drops Hint That Olivia Rodrigo and Stevie Nicks Have Music in ‘Practical Magic 2’
- We Asked 3 Child Psychologists for the Best Question To Ask Kids at the Dinner Table, and They All Said the Same Thing
- This Iconic ’90s Supermodel Revisited Her Steamiest Michael Jackson Video, and Fans Call It the ‘Hottest Video in History’